Drugging cancer genomes

Nature Reviews Drug Discovery

Volumn 12, Issue 12, 2013, Pages 889-890

  Workman, Paul ^a   Al Lazikani, Bissan ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CRIZOTINIB; VEMURAFENIB;

CANCER GENOME; CANCER RESISTANCE; CANCER SURVIVAL; CARCINOGENESIS; CLONAL EVOLUTION; DNA REPAIR; DNA SEQUENCE; EPIGENETICS; FEEDBACK SYSTEM; GENE EXPRESSION; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; MELANOMA; NOTE; PRIORITY JOURNAL; TUMOR GENE; ULTRAVIOLET RADIATION;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; GENE TARGETING; GENOME, HUMAN; HUMANS; NEOPLASMS;

EID: 84889600600     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd4184     Document Type: Note

References (5)

1. Kandoth, C. et al. Mutational landscape and significance across 12 major cancer types. Nature 502, 333-339 (2013)
2. Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546-1558 (2013
3. Futreal, P. A. et al. A census of human cancer genes. Nature Rev. Cancer 4, 177-183 (2004
4. Patel, M. N. et al. Objective assessment of cancer genes for drug discovery. Nature Rev. Drug Discov. 12, 35-50 (2013
5. Halling-Brown, M. D. et al. canSAR: An integrated cancer public translational research and drug discovery resource. Nucleic Acids Res. 40, D947-D956 (2012